HK1211950A1 - Combination therapy of anti-her3 and anti-her2 antibodies her3 her2 - Google Patents

Combination therapy of anti-her3 and anti-her2 antibodies her3 her2

Info

Publication number
HK1211950A1
HK1211950A1 HK15112676.9A HK15112676A HK1211950A1 HK 1211950 A1 HK1211950 A1 HK 1211950A1 HK 15112676 A HK15112676 A HK 15112676A HK 1211950 A1 HK1211950 A1 HK 1211950A1
Authority
HK
Hong Kong
Prior art keywords
her3
her2
combination therapy
antibodies
her2 antibodies
Prior art date
Application number
HK15112676.9A
Other languages
English (en)
Chinese (zh)
Inventor
Frieder Bauss
Birgit Bossenmaier
Thomas Friess
Christian Gerdes
Max Hasmann
Marlene Thomas
Martin Weisser
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1211950A1 publication Critical patent/HK1211950A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15112676.9A 2013-01-11 2015-12-24 Combination therapy of anti-her3 and anti-her2 antibodies her3 her2 HK1211950A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13151076 2013-01-11
PCT/EP2014/050344 WO2014108484A2 (fr) 2013-01-11 2014-01-10 Thérapie de combinaison avec des anticorps anti-her3

Publications (1)

Publication Number Publication Date
HK1211950A1 true HK1211950A1 (en) 2016-06-03

Family

ID=47504772

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112676.9A HK1211950A1 (en) 2013-01-11 2015-12-24 Combination therapy of anti-her3 and anti-her2 antibodies her3 her2

Country Status (19)

Country Link
US (2) US9180185B2 (fr)
EP (1) EP2943508B1 (fr)
JP (1) JP6257646B2 (fr)
KR (1) KR20150093231A (fr)
CN (1) CN104797602A (fr)
AR (1) AR094403A1 (fr)
AU (1) AU2014204795A1 (fr)
CA (1) CA2887508A1 (fr)
CL (1) CL2015001049A1 (fr)
CR (1) CR20150284A (fr)
EA (1) EA201500744A1 (fr)
HK (1) HK1211950A1 (fr)
IL (1) IL238393A0 (fr)
MA (1) MA38273A1 (fr)
MX (1) MX2015008313A (fr)
PH (1) PH12015501071A1 (fr)
SG (1) SG11201503802UA (fr)
TW (1) TW201431559A (fr)
WO (1) WO2014108484A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CA3071678A1 (fr) 2013-04-16 2014-10-23 Genentech,Inc. Variantes de pertuzumab et leur evaluation
EP3143049B1 (fr) 2014-05-14 2019-08-21 F. Hoffmann-La Roche AG Anticorps bispécifiques her3/her2 se liant à la structure en épingle à cheveux béta de her3 et au domaine ii de her2
EP3091033A1 (fr) * 2015-05-06 2016-11-09 Gamamabs Pharma Anticorps anti-her3 humains et leurs utilisations
CN108602890A (zh) 2015-12-11 2018-09-28 瑞泽恩制药公司 用于减少或预防对egfr和/或erbb3阻滞剂具有抗性的肿瘤生长的方法
WO2017102789A1 (fr) * 2015-12-17 2017-06-22 F. Hoffmann-La Roche Ag Polythérapie à base d'anticorps anti-her3 et d'anticorps anti-her2
MA56006A (fr) 2017-01-17 2022-05-04 Hoffmann La Roche Formulations sous-cutanées d'anticorps her2
CA3053749A1 (fr) 2017-02-28 2018-09-07 Kinki University Methode de traitement du cancer du poumon non a petites cellules resistant a l'egfr-tki par administration d'un conjugue anticorps anti-her3-medicament
CN116531511A (zh) 2017-03-02 2023-08-04 豪夫迈·罗氏有限公司 Her2阳性乳腺癌的辅助治疗
HRP20230538T1 (hr) * 2017-06-27 2023-08-04 Regeneron Pharmaceuticals, Inc. Rekombinantne virusne čestice s modificiranim tropizmom i njihove upotrebe za ciljano uvođenje genetičkog materijala u humane stanice
KR20210042909A (ko) * 2018-07-09 2021-04-20 프레시전 인코포레이티드 융합 구조물 및 그의 이용 방법
CN112912109A (zh) 2018-09-20 2021-06-04 第一三共株式会社 通过施用抗her3抗体-药物缀合物治疗her3-突变的癌症
KR20240110556A (ko) * 2021-09-03 2024-07-15 캔써 리서치 테크놀로지 리미티드 Her3 항원-결합 분자를 사용한 암의 치료 및 예방

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
EP1728802A3 (fr) 1996-03-27 2006-12-13 Genentech, Inc. Anticorps de la protèine ErbB3
AU2710597A (en) 1996-06-27 1998-01-14 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
IL139707A0 (en) 1998-05-15 2002-02-10 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
EP1107962B1 (fr) 1998-08-27 2005-02-23 Pfizer Products Inc. Derives de quinolin-2-one utiles en tant qu'agents anticancereux
CZ2001660A3 (cs) 1998-08-27 2002-05-15 Pfizer Products Inc. Alkynylsubstituované chinolin-2-ony, farmaceutické kompozice a způsoby léčení na jejich bázi a způsob výroby těchto sloučenin
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU2124800A (en) 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
IL146954A0 (en) 1999-06-25 2002-08-14 Genentech Inc HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
EP1228766A1 (fr) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Phosphorylation de PYK2 par HER3 induit l'invasion de tumeurs
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
EP1283053A1 (fr) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibiteurs de l'activité de HER3
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003080835A1 (fr) 2002-03-26 2003-10-02 Zensun (Shanghai) Sci-Tech. Ltd. Procedes fondes sur l'utilisation de erbb3 et compositions associees de traitement des neoplasmes
ES2542885T3 (es) 2003-01-22 2015-08-12 Roche Glycart Ag Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
EP1648511A1 (fr) 2003-07-29 2006-04-26 Morphotek, Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
EP2502935B1 (fr) 2003-08-22 2017-03-29 Biogen MA Inc. Anticorps améliorés dotés d'une fonction effectrice altérée et leurs procédés de fabrication
US20050152894A1 (en) 2003-09-05 2005-07-14 Genentech, Inc. Antibodies with altered effector functions
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
CA2567293C (fr) 2004-05-27 2017-05-16 The Regents Of The University Of Colorado Methodes de prediction d'un avantage clinique relativement a des inhibiteurs du recepteur de facteur de croissance epidermique pour des cancereux
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
AU2005282397A1 (en) 2004-09-08 2006-03-16 Genentech, Inc. Methods of using death receptor ligands and CD20 antibodies
CA2587766A1 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
CN101115849A (zh) 2004-12-07 2008-01-30 健泰科生物技术公司 选择her抑制剂疗法的患者
SI1871805T1 (sl) * 2005-02-07 2020-02-28 Roche Glycart Ag Antigen vezavne molekule, ki vežejo EGFR, vektorji, ki te kodirajo in uporabe le-teh
EP1850874B1 (fr) * 2005-02-23 2013-10-16 Genentech, Inc. Extension de la periode menant à la progression de la maladie ou à la survie chez les patients atteints du cancer de l'ovaire par le pertuzumab
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
KR101379568B1 (ko) 2005-08-26 2014-04-08 로슈 글리카트 아게 변형된 세포 신호 활성을 가진 개질된 항원 결합 분자
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
EP2097754B2 (fr) 2006-11-28 2018-01-24 Daiichi Sankyo Europe GmbH Her3 activé servant de marqueur pour prédire l'efficacité thérapeutique
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
PT2162149E (pt) 2007-06-01 2014-02-12 Jackson H M Found Military Med Vacina para a prevenção da recaída do cancro da mama
MX2009012838A (es) 2007-06-06 2009-12-11 Hoffmann La Roche Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
EP2138511A1 (fr) 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 en tant que déterminant pour le pronostic de mélanome
EP2318548B1 (fr) 2008-08-15 2013-10-16 Merrimack Pharmaceuticals, Inc. Procédés, systèmes et produits pour prévoir une réponse de cellules tumorales à un agent thérapeutique, et traitement d'un patient selon la réponse prévue
WO2010052225A1 (fr) 2008-11-04 2010-05-14 F. Hoffmann-La Roche Ag Modulateurs de la signalisation her2 dans des paramètres d'expression de her2 normaux
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
MX2011009729A (es) 2009-03-20 2011-10-14 Genentech Inc Anticuerpos anti-her.
CA2757531A1 (fr) 2009-04-07 2010-10-14 Roche Glycart Ag Anticorps anti-erbb-3/anti-c-met bispecifiques
US8362215B2 (en) 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
WO2011022727A2 (fr) 2009-08-21 2011-02-24 Merrimack Pharmaceuticals, Inc. Anticorps contre l’ectodomaine de erbb3 et leurs utilisations
EP2486052A4 (fr) 2009-10-09 2013-05-01 Merck Sharp & Dohme Génération, caractérisation et utilisations d'anticorps anti-her3
JP5960598B2 (ja) 2009-11-04 2016-08-02 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
NZ600262A (en) 2009-12-22 2013-06-28 Roche Glycart Ag Anti-her3 antibodies and uses thereof
CN102892779B (zh) 2010-02-18 2016-12-21 基因泰克公司 神经调节蛋白拮抗剂及其在治疗癌症中的用途
EP2544680B1 (fr) 2010-03-11 2015-01-14 Merrimack Pharmaceuticals, Inc. Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs
CA2795799C (fr) 2010-04-09 2018-09-25 Aveo Pharmaceuticals, Inc. Anticorps anti-erbb3
WO2012019024A2 (fr) 2010-08-04 2012-02-09 Immunogen, Inc. Molécules se liant à her3 et leurs immunoconjugués
CA2815154A1 (fr) 2010-08-06 2012-02-09 U3 Pharma Gmbh Utilisation d'agents de liaison her3 dans le traitement de la prostate
MX2013002046A (es) 2010-08-20 2013-04-03 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2011307251A1 (en) 2010-09-30 2013-02-28 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-HER3 antibodies
WO2012052230A1 (fr) 2010-10-18 2012-04-26 Mediapharma S.R.L. Anticorps se liant à erbb3
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
DK2635604T3 (en) 2010-11-01 2017-02-27 Symphogen As PAN-HER-ANTIBODY COMPOSITION
ITRM20100577A1 (it) 2010-11-02 2012-05-03 Takis Srl Immunoterapia contro il recettore erbb-3
MX2013010444A (es) 2011-03-15 2014-03-21 Merrimack Pharmaceuticals Inc Superar la resistencia a inhibidores de la via erbb.
SI2766040T1 (sl) 2011-10-14 2019-08-30 F. Hoffmann-La Roche Ag Pertuzumab, Trastuzumab, Docetaxel in Carboplatin za zdravljenje zgodnjega raka dojke
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
ES2758433T3 (es) * 2011-12-05 2020-05-05 Novartis Ag Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
EP2793941A1 (fr) 2011-12-23 2014-10-29 F.Hoffmann-La Roche Ag Articles manufacturés et procédés destinés à la coadministration d'anticorps
US8859797B1 (en) 2012-04-27 2014-10-14 Air Liquide Electronics U.S. Lp Synthesis methods for carbosilanes
CA2872226A1 (fr) 2012-05-02 2013-11-07 Symphogen A/S Compositions d'anticorps pan-her humanises
US9180185B2 (en) * 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies

Also Published As

Publication number Publication date
US20140227255A1 (en) 2014-08-14
EP2943508B1 (fr) 2020-07-15
AR094403A1 (es) 2015-07-29
US20160159912A1 (en) 2016-06-09
KR20150093231A (ko) 2015-08-17
CR20150284A (es) 2015-06-30
CN104797602A (zh) 2015-07-22
SG11201503802UA (en) 2015-08-28
TW201431559A (zh) 2014-08-16
MA38273A1 (fr) 2017-05-31
MX2015008313A (es) 2015-11-11
WO2014108484A3 (fr) 2014-09-04
CA2887508A1 (fr) 2014-07-17
US9180185B2 (en) 2015-11-10
IL238393A0 (en) 2015-06-30
CL2015001049A1 (es) 2015-10-16
PH12015501071A1 (en) 2015-08-03
WO2014108484A2 (fr) 2014-07-17
JP2016504399A (ja) 2016-02-12
EA201500744A1 (ru) 2015-12-30
AU2014204795A1 (en) 2015-04-30
EP2943508A2 (fr) 2015-11-18
JP6257646B2 (ja) 2018-01-10

Similar Documents

Publication Publication Date Title
HK1211950A1 (en) Combination therapy of anti-her3 and anti-her2 antibodies her3 her2
IL304243A (en) Anti-transferrin receptor antibodies and methods of use
IL291446A (en) Anti-trop2 antibodies and methods for their production
IL290295A (en) A combination of antibodies against lag-3 and antibodies against pd-1 for the treatment of tumors
HK1223115A1 (zh) 雙特異性 抗體及使用方法
HK1225998A1 (zh) 用於癌症治療的包含抗ceacam1抗體和抗pd抗體的組合物
EP2994164A4 (fr) Constructions de liaison aux antigènes her2 et her3 bispécifiques
HK1206040A1 (en) Anti-egfr antibodies and uses thereof egfr
HK1220473A1 (zh) 抗-α-突觸核蛋白抗體及使用方法
HK1251969A1 (zh) 抗her2抗體和使用方法
HUE064292T2 (hu) Humán anti-IL-33 semlegesítõ monoklonális antitest
EP2970494A4 (fr) Anticorps monoclonaux spécifiques de her3 pour l'utilisation dans le diagnostic et thérapeutique
PL3480215T3 (pl) Przeciwciało anty-HER2 i jego koniugat
IL240440A0 (en) Antibodies against her2 with a high level of galactosylation and their uses
HK1216754A1 (zh) 抗- 抗體及其使用方法
HK1223950A1 (zh) 單克隆 抗體及其用途
EP2970491A4 (fr) Anticorps monoclonaux contre l'egfr et leurs utilisations
HK1213584A1 (zh) 用於治療癌症的 抗體及方法